Published in Gene on April 01, 2007
Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res (2008) 1.17
New insights into human prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues. Br J Pharmacol (2007) 0.87
Comparison of human chromosome 19q13 and syntenic region on mouse chromosome 7 reveals absence, in man, of 11.6 Mb containing four mouse calcium-sensing receptor-related sequences: relevance to familial benign hypocalciuric hypercalcaemia type 3. Eur J Hum Genet (2009) 0.82
In utero exposure to maternal diabetes impairs vascular expression of prostacyclin receptor in rat offspring. Diabetes (2010) 0.81
High throughput mutagenesis for identification of residues regulating human prostacyclin (hIP) receptor expression and function. PLoS One (2014) 0.79
Long Lasting Microvascular Tone Alteration in Rat Offspring Exposed In Utero to Maternal Hyperglycaemia. PLoS One (2016) 0.78
Comprehensive biochemical analysis of rare prostacyclin receptor variants: study of association of signaling with coronary artery obstruction. J Biol Chem (2010) 0.78
Expression of prostaglandin I2 (prostacyclin) receptor in blood of migraine patients: A potential biomarker. Adv Biomed Res (2015) 0.75
Regulation of the human prostacyclin receptor gene by the cholesterol-responsive SREBP1. J Lipid Res (2012) 0.75
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res (2001) 76.97
dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res (1999) 11.40
Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 4.59
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Coxibs and cardiovascular disease. N Engl J Med (2004) 4.42
GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res (2003) 3.34
Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature (1997) 3.07
COX-2-derived prostacyclin confers atheroprotection on female mice. Science (2004) 2.87
A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem (1999) 2.78
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A (2006) 2.72
Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation (2001) 1.51
Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation (2001) 1.35
Polymorphisms of the beta2-adrenergic receptor and asthma. Am J Respir Crit Care Med (1997) 1.32
Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem (1994) 1.09
Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. Annu Rev Pharmacol Toxicol (2001) 1.08
Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem (2001) 1.06
Two novel mutations in the gonadotropin-releasing hormone receptor gene in Brazilian patients with hypogonadotropic hypogonadism and normal olfaction. J Clin Endocrinol Metab (2001) 1.04
Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors. Circulation (2001) 0.95
Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism. J Biol Chem (2002) 0.92
Distribution analysis of nonsynonymous polymorphisms within the G-protein-coupled receptor gene family. Genomics (2003) 0.85
Structural organization and chromosomal assignment of the human prostacyclin receptor gene. Genomics (1995) 0.85
Low hanging fruit: a subset of human cSNPs is both highly non-uniform and predictable. Gene (2003) 0.83
False positive non-synonymous polymorphisms of G-protein coupled receptor genes. FEBS Lett (2002) 0.83
Mutations in the vasopressin V2 receptor gene in families with nephrogenic diabetes insipidus and functional expression of the Q-2 mutant. Cell Mol Biol (Noisy-le-grand) (1994) 0.81
Genetic polymorphisms in drug-metabolizing enzymes and drug targets. Mol Genet Metab (2001) 0.80
Polymorphic G-protein-coupled receptors and associated diseases. Receptors Channels (2002) 0.78
In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses (2005) 3.89
Ten-eleven translocation-2 (TET2) is a master regulator of smooth muscle cell plasticity. Circulation (2013) 2.95
Usefulness of the serum electrolyte panel in the management of pediatric dehydration treated with intravenously administered fluids. Pediatrics (2004) 2.92
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet (2013) 2.91
A randomized, controlled trial of i.v. versus i.m. ketamine for sedation of pediatric patients receiving emergency department orthopedic procedures. Ann Emerg Med (2006) 2.53
A prospective study of the incidence of childhood celiac disease. J Pediatr (2003) 2.50
Evaluating changes in coronary artery calcium: an analytic method that accounts for interscan variability. AJR Am J Roentgenol (2004) 2.26
Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med (2014) 2.15
G protein Galphai functions immediately downstream of Smoothened in Hedgehog signalling. Nature (2008) 1.88
Cancer after total joint arthroplasty: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2006) 1.78
Apelin-APJ signaling is a critical regulator of endothelial MEF2 activation in cardiovascular development. Circ Res (2013) 1.68
Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatr Pulmonol (2003) 1.62
Light-driven activation of beta 2-adrenergic receptor signaling by a chimeric rhodopsin containing the beta 2-adrenergic receptor cytoplasmic loops. Biochemistry (2005) 1.48
Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control. Diabetes Care (2003) 1.43
Opsin is a phospholipid flippase. Curr Biol (2011) 1.27
Characterization of acute liver failure and development of a continuous risk of death staging system in children. J Hepatol (2005) 1.20
Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res (2008) 1.17
The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am J Physiol Heart Circ Physiol (2006) 1.12
Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol (2012) 1.10
A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. Sex Transm Dis (2008) 1.09
A novel pathway for nickel-induced interleukin-8 expression. J Biol Chem (2002) 1.08
Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J Clin Invest (2011) 1.07
Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects. Oncogene (2002) 1.06
Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of rapamycin complex 1 and FoxO4. Arterioscler Thromb Vasc Biol (2011) 1.05
NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS One (2011) 1.04
Cardioprotective prostacyclin signaling in vascular smooth muscle. Prostaglandins Other Lipid Mediat (2006) 1.04
Critical role of transmembrane segment zinc binding in the structure and function of rhodopsin. J Biol Chem (2004) 1.03
Time-varying risk factors for long-term mortality after coronary artery bypass graft surgery. Ann Thorac Surg (2006) 1.02
Rhodopsin and retinitis pigmentosa: shedding light on structure and function. Receptors Channels (2002) 1.00
The critical role of transmembrane prolines in human prostacyclin receptor activation. Mol Pharmacol (2002) 0.99
The future of HIV prevention: prospects for an effective anti-HIV microbicide. Infect Dis Clin North Am (2007) 0.99
The unique ligand-binding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling. J Biol Chem (2002) 0.97
Vascular smooth muscle cell-derived adiponectin: a paracrine regulator of contractile phenotype. J Mol Cell Cardiol (2011) 0.93
Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism. J Biol Chem (2002) 0.92
Tumor necrosis factor induces sodium retention in diabetic rats through sequential effects on distal tubule cells. Kidney Int (2004) 0.92
Site-directed mutations and the polymorphic variant Ala160Thr in the human thromboxane receptor uncover a structural role for transmembrane helix 4. PLoS One (2012) 0.92
Prostacyclin primes pregnant human myometrium for an enhanced contractile response in parturition. J Clin Invest (2008) 0.92
Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. Prostaglandins Other Lipid Mediat (2006) 0.91
Clusters of transmembrane residues are critical for human prostacyclin receptor activation. Biochemistry (2004) 0.91
Versatility and differential roles of cysteine residues in human prostacyclin receptor structure and function. J Biol Chem (2006) 0.91
Aldose reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets. Circulation (2014) 0.90
Evaluating the American Academy of Pediatrics diagnostic standard for Streptococcus pyogenes pharyngitis: backup culture versus repeat rapid antigen testing. Pediatrics (2003) 0.90
Adenylyl cyclase type 6 overexpression selectively enhances beta-adrenergic and prostacyclin receptor-mediated inhibition of cardiac fibroblast function because of colocalization in lipid rafts. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.89
Eight-year trends of cardiometabolic morbidity and mortality in patients with schizophrenia. Gen Hosp Psychiatry (2012) 0.88
Retinitis pigmentosa rhodopsin mutations L125R and A164V perturb critical interhelical interactions: new insights through compensatory mutations and crystal structure analysis. J Biol Chem (2003) 0.87
Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. Pharmacogenet Genomics (2008) 0.87
Polyantigenic interferon-γ responses are associated with protection from TB among HIV-infected adults with childhood BCG immunization. PLoS One (2011) 0.86
Screening mammography intervals among postmenopausal hormone therapy users and nonusers. Cancer Causes Control (2009) 0.85
Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease. Curr Atheroscler Rep (2009) 0.85
Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol (2010) 0.84
An eicosanoid-centric view of atherothrombotic risk factors. Cell Mol Life Sci (2012) 0.84
New insights into structural determinants for prostanoid thromboxane A2 receptor- and prostacyclin receptor-G protein coupling. Mol Cell Biol (2012) 0.83
Outcomes associated with pediatric after-hours care by call centers: a multicenter study. Ambul Pediatr (2003) 0.83
Efficacy and patient perception of Grenz ray therapy in the treatment of dermatoses refractory to other medical therapy. Dermatitis (2008) 0.82
Discovery of breast cancers within 1 year of a normal screening mammogram: how are they found? Ann Fam Med (2006) 0.81
Conserved rhodopsin intradiscal structural motifs mediate stabilization: effects of zinc. Biochemistry (2009) 0.81
Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol (2009) 0.81
Exploration of the antiplatelet activity profile of betulinic acid on human platelets. J Agric Food Chem (2012) 0.80
Biased suppression of TP homodimerization and signaling through disruption of a TM GxxxGxxxL helical interaction motif. J Lipid Res (2013) 0.80
Insulin lispro therapy in pregnancies complicated by type 1 diabetes: glycemic control and maternal and fetal outcomes. Endocr Pract (2003) 0.80
Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger. J Pediatr (2004) 0.80
BRCA1 splice variants exhibit overlapping and distinct transcriptional transactivation activities. J Cell Biochem (2003) 0.79
Prostacyclin: an inflammatory paradox. Front Pharmacol (2011) 0.79
Shp shape: FAKs about hypertrophy. Circ Res (2008) 0.78
Human thromboxane A2 receptor genetic variants: in silico, in vitro and "in platelet" analysis. PLoS One (2013) 0.78
Comprehensive biochemical analysis of rare prostacyclin receptor variants: study of association of signaling with coronary artery obstruction. J Biol Chem (2010) 0.78
The human prostacyclin receptor from structure function to disease. Prog Mol Biol Transl Sci (2009) 0.77
Leukaemia-associated Rho guanine nucleotide exchange factor (LARG) plays an agonist specific role in platelet function through RhoA activation. Thromb Haemost (2016) 0.77
Autoantibodies in mothers of children with neonatal liver disease. J Pediatr Gastroenterol Nutr (2003) 0.76
Greater preexisting interferon γ responses to mycobacterial antigens and lower bacillary load during HIV-associated tuberculosis. J Infect Dis (2013) 0.76
Regulation of VWF expression, and secretion in health and disease. Curr Opin Hematol (2016) 0.75
101 Medicare Expenditures for Elderly Patients Undergoing Surgical Clipping or Endovascular Intervention for Subarachnoid Hemorrhage. Neurosurgery (2016) 0.75